首页> 外文期刊>Quimica nova >Leishmania proteases: new targets for rational drug development
【24h】

Leishmania proteases: new targets for rational drug development

机译:利什曼原虫蛋白酶:合理药物开发的新目标

获取原文
获取外文期刊封面目录资料

摘要

Leishmania causes tegumental and visceral diseases called leishmaniasis. Disease control is possible interrupting the transmission cycle, but HIV co-infection, chemotheraphy toxicity and lack of a vaccine are paramount difficulties. So, is necessary to study new Leishmania molecules and investigate the possibility to develop rational drugs using these molecules as targets. Leishmania express many peptidases during their life, and cysteine are the most abundant protease and many inhibitors were developed but failed to kill parasites. On the other hand, inhibitors of serine proteases killed promastigotes, indicating the possibility of these enzymes to be important targets in the development of anti-Leishmania drugs.
机译:利什曼原虫引起被称为利什曼原虫病的皮肤和内脏疾病。疾病控制可能会中断传播周期,但HIV合并感染,化学疗法毒性和缺乏疫苗是最重要的困难。因此,有必要研究新的利什曼原虫分子并研究使用这些分子作为靶标开发合理药物的可能性。利什曼原虫在其一生中表达许多肽酶,而半胱氨酸是最丰富的蛋白酶,开发了许多抑制剂,但未能杀死寄生虫。另一方面,丝氨酸蛋白酶的抑制剂杀死了前鞭毛体,这表明这些酶可能成为抗利什曼原虫药物开发中的重要靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号